Georgios Batsios

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3515895/publications.pdf

Version: 2024-02-01

1039406 1058022 35 211 9 14 citations g-index h-index papers 36 36 36 284 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Scientific Reports, 2019, 9, 10521.	1.6	36
2	Hybrid multiband excitation multiecho acquisition for hyperpolarized ¹³ C spectroscopic imaging. Magnetic Resonance in Medicine, 2015, 73, 1713-1717.	1.9	30
3	MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics, 2020, 10, 8757-8770.	4.6	23
4	Non-invasive assessment of telomere maintenance mechanisms in brain tumors. Nature Communications, 2021, 12, 92.	5.8	21
5	Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Cancer Research, 2020, 80, 5098-5108.	0.4	18
6	Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas. Neuro-Oncology, 2021, 23, 1509-1522.	0.6	15
7	Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer. Clinical Cancer Research, 2022, 28, 3526-3536.	3.2	15
8	In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. Scientific Reports, 2019, 9, 3402.	1.6	12
9	In vivo detection of Î ³ -glutamyl-transferase up-regulation in glioma using hyperpolarized Î ³ -glutamyl-[1-13C]glycine. Scientific Reports, 2020, 10, 6244.	1.6	12
10	Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas. Neuro-Oncology, 2022, 24, 1101-1112.	0.6	11
11	Imaging 6-Phosphogluconolactonase Activity in Brain Tumors In Vivo Using Hyperpolarized δ-[1-13C]gluconolactone. Frontiers in Oncology, 2021, 11, 589570.	1.3	9
12	EXTH-20. HYPERPOLARIZED [2-13C] PYRUVATE TO [5-13C] GLUTAMATE AS BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO TEMOZOLOMIDE THERAPY. Neuro-Oncology, 2019, 21, vi86-vi86.	0.6	4
13	Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma. Neuro-Oncology, 2022, , .	0.6	3
14	EXTH-76. 1H AND HYPERPOLARIZED 13C MRS BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO TEMOZOLOMIDE THERAPY. Neuro-Oncology, 2018, 20, vi101-vi101.	0.6	1
15	Acquisition and quantification pipeline for in vivo hyperpolarized ¹³ C MR spectroscopy. Magnetic Resonance in Medicine, 2022, 87, 1673-1687.	1.9	1
16	Multi-echo single-shot EPI for hyperpolarized 13C cardiac metabolic imaging of small animals. Journal of Cardiovascular Magnetic Resonance, 2013, 15, P217.	1.6	0
17	EXTH-51. PI3K/mTOR INHIBITION LEADS TO REDUCTION IN 2HG PRODUCTION AND CELL PROLIFERATION IN IDH1 MUTANT CELLS. Neuro-Oncology, 2017, 19, vi83-vi84.	0.6	O
18	EXTH-35. IN VIVO 1H MRS DETECTS REDUCED 2HG PRODUCTION IN IDH1 MUTANT GLIOMAS TREATED WITH A DUAL PI3K/MTOR INHIBITOR. Neuro-Oncology, 2018, 20, vi92-vi92.	0.6	0

#	Article	IF	CITATIONS
19	CBMT-02. UP-REGULATION OF Γ-GLUTAMYL-TRANSFERASE CAN BE USED TO IMAGE GLIOBLASTOMA USING HYPERPOLARIZED Γ-GLUTAMYL-[1-13C]GLYCINE MRS. Neuro-Oncology, 2019, 21, vi33-vi33.	0.6	0
20	CBMT-08. IN VIVO EVALUATION OF PENTOSE PHOSPHATE PATHWAY ACTIVITY IN ORTHOTOPIC GLIOMA USING HYPERPOLARIZED δ-[1-13C]GLUCONOLACTONE. Neuro-Oncology, 2019, 21, vi34-vi34.	0.6	0
21	CBMT-41. IMAGING A HALLMARK OF CANCER: HYPERPOLARIZED 13C-MAGNETIC RESONANCE SPECTROSCOPY CAN NON-INVASIVELY MONITOR TERT EXPRESSION IN LOW-GRADE GLIOMAS IN VIVO. Neuro-Oncology, 2019, 21, vi42-vi42.	0.6	0
22	TBMT-01. HYPERPOLARIZED \hat{l} -[1-13C]GLUCONOLACTONE MONITORS TERT-INDUCED ELEVATION IN PENTOSE PHOSPHATE PATHWAY FLUX IN BRAIN TUMORS IN VIVO. Neuro-Oncology Advances, 2021, 3, i20-i20.	0.4	0
23	BIMG-08. DEUTERIUM MAGNETIC RESONANCE SPECTROSCOPY USING 2H-PYRUVATE ALLOWS NON-INVASIVE IN VIVO IMAGING OF TERT EXPRESSION IN BRAIN TUMORS. Neuro-Oncology Advances, 2021, 3, i2-i2.	0.4	0
24	BIMG-05. TO BE OR NOT TO BE GLYCOLYTIC: DEUTERATED GLUCOSE-BASED ASSESSMENT OF THE WARBURG EFFECT ALLOWS NON-INVASIVE IMAGING OF TUMOR BURDEN AND TREATMENT RESPONSE IN MUTANT IDH GLIOMAS IN VIVO. Neuro-Oncology Advances, 2021, 3, i1-i2.	0.4	0
25	BIMG-02. IMAGING IMMORTALITY: TERT EXPRESSION ALTERS GLUCOSE METABOLISM IN LOW-GRADE GLIOMAS IN A MANNER THAT CAN BE LEVERAGED FOR NONINVASIVE METABOLIC IMAGING. Neuro-Oncology Advances, 2021, 3, i1-i1.	0.4	0
26	Abstract 5263:1H and 13C MRS-based metabolic markers of IDH1 mutant glioma response to temozolomide therapy. , 2019, , .		0
27	NIMG-51. DEUTERIUM METABOLIC IMAGING OF BRAIN TUMOR IMMORTALITY USING 2H-PYRUVATE. Neuro-Oncology, 2021, 23, vi140-vi141.	0.6	0
28	TAMI-40. PEDIATRIC H3K27M MUTANT GLIOMAS UNDERGO METABOLIC REPROGRAMMING THAT CAN BE LEVERAGED FOR NON-INVASIVE METABOLIC IMAGING. Neuro-Oncology, 2021, 23, vi206-vi207.	0.6	0
29	EXTH-46. MRS BASED BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO THE IDH INHIBITOR BAY-1436032. Neuro-Oncology, 2021, 23, vi173-vi173.	0.6	0
30	BIOM-14. METABOLIC BIOMARKERS OF TERT-TARGETED THERAPY FOR HUMAN GLIOBLASTOMA DETECTED BY MAGNETIC RESONANCE SPECTROSCOPY. Neuro-Oncology, 2021, 23, vi13-vi13.	0.6	0
31	BIOM-10. PRECLINICAL PLATFORM FOR THE IDENTIFICATION OF DEUTERIUM MAGNETIC RESONANCE SPECTROSCOPY-BASED BIOMARKERS OF BRAIN TUMOR METABOLISM. Neuro-Oncology, 2021, 23, vi12-vi12.	0.6	0
32	NIMG-50. DEUTERIUM METABOLIC IMAGING OF THE ALTERNATIVE LENGTHENING OF TELOMERES PATHWAY REPORTS ON TUMOR BURDEN AND PSEUDOPROGRESSION IN LOW-GRADE GLIOMAS. Neuro-Oncology, 2021, 23, vi140-vi140.	0.6	0
33	BIOM-19. METABOLIC ALTERATION INDUCED BY SELECTIVE KNOCK DOWN OF GABPB1L IN U251 CELLS. Neuro-Oncology, 2020, 22, ii5-ii6.	0.6	0
34	TAMI-08. A TALE OF TWO TELOMERE MAINTENANCE MECHANISMS: TERT EXPRESSION AND THE ALT PATHWAY INDUCE UNIQUE MRS-DETECTABLE METABOLIC REPROGRAMMING IN LOW-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, ii214-ii214.	0.6	0
35	Abstract 5263: $<$ sup>1 $<$ /sup>H and $<$ sup>13 $<$ /sup>C MRS-based metabolic markers of IDH1 mutant glioma response to temozolomide therapy., 2019,,.		0